Preemption Argument In Drug/Cosmetic Dispute Likely Falls Short Of Supreme Court
This article was originally published in The Tan Sheet
Executive Summary
Federal law does not preempt Allergan's suit alleging Athena Cosmetics' RevitaLash competes unfairly against the drug firm's Latisse treatment in California, according to a Supreme Court brief filed by Solicitor General Donald Verrilli. Athena argues the absence of FDA action against its eyelash enhancers signals that its cosmetic positioning is lawful.
You may also be interested in...
Supreme Court Asked To Consider Pre-emption In Drug Vs. Cosmetic Litigation
The Supreme Court asks the Solicitor General for an amicus in a case examining whether FDA regulation pre-empts state litigation on the cosmetics/drugs regulatory divide. The case could have implications for the personal care industry as states increasingly claim oversight by clarifying FDA’s division between drugs and cosmetics.
In Brief: Coty Eyes OPI Growth; RevitaLash Is Back; Garnier Pulled From China
Coty aims to drive development of its OPI nail brand in the U.K. with the acquisition of distributor Lena White. More news in brief.
FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims
An April 18 FDA warning letter to Lifetech Resources LLC demonstrates that cosmetics firms will be held accountable when their websites feature third-party claims and testimonials that cross into drug marketing territory.